Takeaway

• In patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), panitumumab led to better overall survival (OS) compared to bevacizumab in combination with standard chemotherapy (mFOLFOX6), especially in left-sided tumours.
• Panitumumab plus mFOLFOX6 demonstrated the longest survival ever reported in the first-line unresectable mCRC phase 3 trials.
• This study...